echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > WuXi Biologics intends to establish a joint venture company for US$120 million to develop and produce ADCs and other drugs

    WuXi Biologics intends to establish a joint venture company for US$120 million to develop and produce ADCs and other drugs

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of March 30, WuXi Biologics (02269) issued an announcement stating that the company plans to cooperate with Shanghai Hequan Pharmaceutical Co.


    According to the announcement, WuXi XDC will be engaged in the contract development and production of antibody-conjugated drugs (ADC) and other bio-conjugated drugs.


    According to the announcement, WuXi Biologics and Hequan Pharmaceuticals will strive to build WuXi XDC into an integrated and end-to-end contract development and production service (CDMO) company, specializing in the development and production of ADCs and other bioconjugate drugs.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.